De Novo Classification: FDA Pathway for Novel Medical Devices

Understanding FDA's Device Classification System

FDA classifies medical devices into three regulatory classes based on the level of control necessary to ensure safety and effectiveness:

• Class I (General Controls) — lowest risk devices, subject to general controls including establishment registration, device listing, good manufacturing practices (QSR/QMSR), labeling, and premarket notification (though most Class I devices are exempt from 510(k)). Examples: bandages, tongue depressors, examination gloves.
• Class II (Special Controls) — moderate risk devices, subject to general controls plus special controls (guidance documents, performance standards, postmarket surveillance). Most Class II devices require a 510(k) premarket notification. Examples: powered wheelchairs, pregnancy test kits, infusion pumps.
• Class III (Premarket Approval) — highest risk devices, subject to general controls and premarket approval (PMA) requirements. PMA requires clinical evidence of safety and effectiveness. Examples: heart valves, implantable pacemakers, silicone breast implants.

When a manufacturer develops a truly novel device — one that has no legally marketed predicate — the device is automatically classified as Class III under Section 513(f)(1) of the FD&C Act. However, many novel devices are low-to-moderate risk and do not warrant the extensive PMA requirements. The De Novo pathway provides a route to reclassify these devices into Class I or Class II.

De Novo vs. 510(k) vs. PMA

Understanding when to use each pathway is one of the most important strategic decisions in medical device regulatory planning:

510(k) — Premarket Notification

The 510(k) pathway is appropriate when your device is substantially equivalent to an already-marketed (predicate) device. You demonstrate that your device has the same intended use and either the same technological characteristics or different characteristics that do not raise new questions of safety and effectiveness. The 510(k) is the most common pathway, accounting for the majority of new device clearances each year.

PMA — Premarket Approval

The PMA pathway is required for Class III (high-risk) devices. PMA requires extensive evidence of safety and effectiveness, typically including clinical trial data. The PMA process is more time-consuming and expensive than 510(k), with review timelines of 180 days or more and significant clinical data requirements. PMA is the most stringent type of device marketing application.

De Novo — Classification Request

The De Novo pathway fills the gap between 510(k) and PMA. It is designed for novel devices that are low-to-moderate risk but have no predicate. Without the De Novo pathway, these devices would default to Class III and require PMA — an unnecessarily burdensome process for lower-risk innovations.

The De Novo Process: Step by Step

There are two ways to reach the De Novo pathway:

Direct De Novo Request

Since the 21st Century Cures Act (2016), manufacturers can submit a De Novo classification request directly, without first submitting and receiving a "not substantially equivalent" (NSE) determination on a 510(k). This is now the preferred and most common approach.

Post-NSE De Novo

Alternatively, a manufacturer can submit a 510(k), receive an NSE determination (because no predicate exists), and then submit a De Novo request within 30 days. This approach is less common since the direct pathway became available.

The De Novo submission must include:

1. Device description — detailed description of the device, its design, materials, components, and principles of operation
2. Intended use and indications for use — clearly define the purpose of the device and the specific conditions or patient populations it is intended for
3. Risk analysis — identify all risks associated with the device and propose mitigations. This is a critical element that distinguishes the De Novo from a 510(k).
4. Proposed classification — specify whether you are requesting Class I or Class II classification, with justification
5. Proposed special controls (for Class II) — define the special controls that, together with general controls, provide reasonable assurance of safety and effectiveness
6. Performance data — bench testing, biocompatibility testing, electrical safety testing, software verification/validation, and any clinical data supporting safety and effectiveness
7. Labeling — proposed device labeling, including instructions for use

What Happens After a De Novo Grant

When FDA grants a De Novo request, several important things happen:

• New device classification created — FDA creates a new regulatory classification (product code and regulation number) for the device type. This classification is published in the Federal Register.
• Special controls order issued — for Class II devices, FDA issues a De Novo classification order that specifies the special controls that apply to the new device type. These special controls become binding on all subsequent devices classified under this type.
• New predicate established — the De Novo device becomes the predicate for future 510(k) submissions from other manufacturers who develop substantially equivalent devices. This is strategically significant — as the first-to-market manufacturer, you define the predicate.
• Marketing authorization — the manufacturer receives a De Novo grant letter (DEN number) authorizing marketing of the device. This is equivalent in effect to a 510(k) clearance for purposes of marketing the device.

The creation of a new device type is one of the most valuable outcomes of the De Novo pathway. It establishes the regulatory framework for an entire category of similar devices and gives the original manufacturer a first-mover advantage.

Recent De Novo Examples and Trends

The De Novo pathway has seen significant growth in recent years, with FDA granting an increasing number of De Novo requests across diverse device categories. Notable recent examples include:

• Artificial intelligence/machine learning (AI/ML) devices — many AI-based diagnostic tools have used the De Novo pathway because they represent novel technology without existing predicates. Examples include AI-powered retinal screening systems and AI-based electrocardiogram analysis tools.
• Digital health devices — software-as-a-medical-device (SaMD) products, wearable health monitors, and digital therapeutics have frequently used the De Novo pathway.
• Novel diagnostics — next-generation sequencing-based diagnostics, companion diagnostics, and rapid molecular tests for infectious diseases.
• Innovative surgical tools — robotic surgical systems, novel energy-based surgical devices, and advanced wound closure technologies.

FDA data shows that De Novo requests have roughly tripled over the past decade, reflecting both the growing innovation in medical technology and FDA's efforts to make the pathway more accessible (particularly through the direct De Novo option added by the 21st Century Cures Act).

The average review time for De Novo requests has varied but generally runs 150–300+ days, depending on the complexity of the device and the number of additional information requests from FDA. Pre-submission meetings with FDA are strongly recommended to align expectations before filing.

Strategic Considerations for De Novo Submissions

If you are considering the De Novo pathway, keep these strategic factors in mind:

• Pre-submission meeting — FDA strongly encourages a pre-submission (Pre-Sub) meeting before filing a De Novo request. This allows you to discuss your device description, proposed intended use, proposed classification, and testing strategy with FDA reviewers before investing in a full submission.
• Risk analysis quality — the risk analysis is arguably the most critical element of a De Novo submission. It must comprehensively identify risks and propose specific mitigations (special controls) that adequately address each risk. Weak risk analyses are a common reason for additional information requests.
• Special controls definition — the special controls you propose will apply to the entire device type going forward. Craft them carefully — overly broad controls may be burdensome for future iterations of your own device, while overly narrow controls may not adequately address the risks.
• Establishment registration — before marketing a device, you must register your establishment with FDA under 21 CFR Part 807 and list the device. Foreign establishments must designate a U.S. Agent and pay the annual MDUFA establishment registration fee.
• Quality system compliance — your manufacturing facility must comply with the QMSR (21 CFR Part 820) requirements before commercial distribution. FDA may conduct a pre-market inspection.
• Post-market obligations — once on the market, you must comply with Medical Device Reporting (MDR) requirements, corrections and removals reporting, and any postmarket surveillance conditions specified in the De Novo order.

The De Novo pathway has become an increasingly important tool for innovative device companies. By creating new device classifications, it enables breakthrough technologies to reach patients through a proportionate regulatory pathway without the cost and time burden of PMA.